Crescent Biopharma reports preliminary Q2 2026 cash of $171.6M

CRESCENT BIOPHARMA, INC.

Cash and cash equivalents estimated at $171.6M as of June 30, 2026.
Preliminary, unaudited data subject to completion of financial closing procedures.
PricewaterhouseCoopers has not audited, reviewed, or compiled the estimate.

item 2.02

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-048151

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.